Aquatic Capital Management LLC Purchases New Shares in Elevance Health, Inc. $ELV

Aquatic Capital Management LLC acquired a new position in Elevance Health, Inc. (NYSE:ELV) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 35,982 shares of the company’s stock, valued at approximately $11,627,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Elevance Health by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock valued at $7,431,322,000 after purchasing an additional 141,747 shares in the last quarter. Wellington Management Group LLP raised its stake in Elevance Health by 4.8% in the third quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock worth $2,139,473,000 after buying an additional 303,099 shares in the last quarter. Sanders Capital LLC lifted its holdings in Elevance Health by 24.7% in the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock worth $2,265,773,000 after buying an additional 1,152,440 shares during the period. Artisan Partners Limited Partnership lifted its holdings in Elevance Health by 24.5% in the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after buying an additional 901,626 shares during the period. Finally, First Eagle Investment Management LLC boosted its position in Elevance Health by 25.0% during the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock valued at $1,292,029,000 after acquiring an additional 798,457 shares in the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health Price Performance

ELV stock opened at $291.69 on Monday. The firm has a 50 day moving average price of $338.25 and a 200-day moving average price of $334.45. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $458.75. The firm has a market capitalization of $64.38 billion, a price-to-earnings ratio of 11.61, a PEG ratio of 1.61 and a beta of 0.51. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping the consensus estimate of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. During the same quarter in the prior year, the business posted $3.84 EPS. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities research analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be paid a $1.72 dividend. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s payout ratio is currently 27.39%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ELV shares. Mizuho decreased their target price on Elevance Health from $413.00 to $350.00 and set an “outperform” rating for the company in a research report on Wednesday, March 11th. Royal Bank Of Canada cut Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price for the company. in a research note on Tuesday, February 3rd. Wolfe Research set a $425.00 price target on Elevance Health and gave the company an “outperform” rating in a research report on Thursday, January 8th. TD Cowen reaffirmed a “buy” rating on shares of Elevance Health in a research note on Wednesday, November 26th. Finally, JPMorgan Chase & Co. increased their price objective on Elevance Health from $394.00 to $397.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Twelve research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $387.40.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.